

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listing of claims in this application.

### **LISTING OF CLAIMS**

1-45. (Cancelled)

46. (Currently Amended) A double-stranded short interfering RNA (siRNA) molecule comprising a sense RNA strand and an antisense RNA strand, wherein the sense RNA strand comprises the sequence 5'-ucgagaccgugggacau-3' (SEQ ID NO: 6).

47. (Previously Presented) A composition comprising the double-stranded siRNA molecule of claim 46 and a suitable carrier.

48. (Previously Presented) The composition of claim 47, further comprising an additional double-stranded nucleic acid molecule.

49. (Previously Presented) The composition of claim 48, wherein the additional double-stranded nucleic acid molecule decreases the expression of a VEGFR1 or VEGFR2 gene.

50. (Previously Presented) The composition of claim 49, wherein the additional double-stranded nucleic acid molecule decreases the expression of human VEGFR1.

51. (Previously Presented) The composition of claim 49, wherein the additional double-stranded nucleic acid molecule decreases the expression of human VEGFR2.

52. (Previously Presented) A composition comprising:

(a) the double-stranded siRNA molecule of claim 46,

(b) a double-stranded nucleic acid molecule that decreases the expression of human VEGFR1; and

(c) a double-stranded nucleic acid molecule that decreases the expression of human VEGFR2.

53. (Previously Presented) The composition of claim 47, further comprising a polymeric synthetic nucleic acid carrier.

54. (Previously Presented) The composition of claim 53, wherein the polymeric synthetic nucleic acid carrier comprises a cationic polymer.

55. (Previously Presented) The composition of claim 54, wherein the cationic polymer is an amino acid copolymer.

56. (Previously Presented) The composition of claim 55, wherein the amino acid copolymer comprises histidine and lysine.

57. (Previously Presented) The composition of claim 53, further comprising a targeting moiety.

58. (Previously Presented) The composition of claim 57, wherein the targeting moiety comprises a peptide.

59. (Previously Presented) The composition of claim 58, wherein the peptide comprises RGD amino acid sequence.

60. (Previously Presented) The composition of claim 53, wherein the polymeric synthetic nucleic acid carrier comprises a hydrophilic polymer.

61. (Previously Presented) The composition of claim 60, wherein the hydrophilic polymer comprises polyethyleneglycol.

62. (Withdrawn) A method for reducing angiogenesis in a subject in need thereof, comprising the step of administering to the subject the double-stranded siRNA molecule of claim 46 or the composition of any one of claims 47, 49 and 52.

63. (Withdrawn) A method of reducing tumor growth in a subject in need thereof, comprising the step of administering to the subject the double-stranded siRNA molecule of claim 46 or the composition of any one of claims 47, 49 and 52.

64. (Withdrawn) A method for decreasing the VEGF protein level in a cell, comprising introducing into the cell the double-stranded siRNA molecule of claim 46 or the composition of any one of claims 47, 49 and 52.